An Overview of the Activities of Cefiderocol Against Sensitive and Multi-drug-Resistant (MDR) Bacteria
MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol.20, no.18, pp.1908-1916, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Review
- Volume: 20 Issue: 18
- Publication Date: 2020
- Doi Number: 10.2174/1389557520666200818211405
- Journal Name: MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
- Page Numbers: pp.1908-1916
- Çukurova University Affiliated: Yes
Abstract
The need for new therapeutics and drug delivery systems has become necessary owing to the public health concern associated with the emergence of multidrug-resistant microorganisms. Among the newly discovered therapeutic agents is cefiderocol, which was discovered by Shionogi Company, Japan as an injectable sideropbore cepbalosporin. Just like the other beta-lactam antibiotics, cefiderocol exhibits antibacterial activity via cell wall synthesis inhibition, especially in Gram negative bacteria (GNB); it binds to the penicillin-binding proteins, but its unique attribute is that it crosses the periplasmic space of bacteria owing to its siderophore-like attribute; it also resists the activity of beta-lactamases. Among all the synthesized compounds with the modified C-7 side chain, cefiderocol (3) presented the best and well-balanced activity against multi-drug resistant (MDR) Gram negative bacteria, including those that are resistant to carbapenem. In this article, an overview of the recent studies on cefiderocol was presented.